New Delhi – India’s ambassador to China, Vikram Doraiswami, used a press briefing in Beijing on Tuesday to argue that a surge in Chinese foreign direct investment (FDI) in India could deepen the bilateral relationship, while urging Chinese buyers to broaden purchases of Indian goods, especially pharmaceuticals, where India enjoys a global competitive edge.
What happened
Doraiswami highlighted that Chinese FDI in India has risen sharply, reaching a record $13.5 billion in the 2023‑24 fiscal year, according to India’s Ministry of Commerce. He described the inflow as “a vote of confidence in India’s growth story and a foundation for a larger, more resilient relationship.” The ambassador also noted that India’s export basket to China remains modest, accounting for roughly $6 billion in the last fiscal year, a small fraction of the $84 billion in imports from China.
“India has the capacity and quality to supply more, particularly in pharmaceuticals, medical devices, and engineered goods,” Doraiswami said, citing India’s status as the world’s third‑largest generic drug producer. He said both governments are discussing ways to streamline customs procedures and reduce non‑tariff barriers, and referenced ongoing negotiations on a “comprehensive economic partnership” that could address certification recognition and intellectual‑property issues critical for Indian pharma firms seeking entry into the Chinese market.
A spokesperson for the Chinese Ministry of Commerce welcomed the remarks, affirming China’s commitment to “mutual benefit and win‑win cooperation” with India, though no specific figures on forthcoming Chinese investment projects were disclosed.
Why it matters
The ambassador’s remarks come at a time when New Delhi and Beijing are navigating a complex geopolitical environment marked by heightened U.S. scrutiny of China and shifting global supply‑chain dynamics. By emphasizing pharmaceuticals—a sector where India combines low‑cost production with a robust domestic industry—the Indian government is seeking to diversify its export markets and reduce reliance on Western pharmaceutical buyers.
If Chinese investors increase stakes in Indian manufacturing, the potential benefits include technology transfer, higher export quality, and a narrowing of the long‑standing trade imbalance that sees India import far more from China than it exports. The $13.5 billion of Chinese FDI, the highest on record, could serve as a catalyst for deeper integration of Indian supply chains into Chinese‑led value chains, provided regulatory frictions are resolved.
Background and context
India‑China trade has been heavily skewed toward Chinese exports. In the 2022‑23 fiscal year, India imported $84 billion worth of goods from China while exporting only $6 billion, creating a persistent trade deficit. Over the past decade, Chinese investment in India has grown steadily, driven by sectors such as electronics, automotive components, and renewable energy. The latest fiscal year’s $13.5 billion inflow represents a continuation of that trend, reflecting Chinese firms’ confidence in India’s market size and reform agenda.
Pharmaceuticals are a particular focus for India. The country is the world’s third‑largest producer of generic medicines, supplying affordable drugs to over 200 countries. Indian firms have faced regulatory hurdles in China, including divergent drug‑approval standards and certification requirements, which have limited their market penetration despite competitive pricing. The “comprehensive economic partnership” under discussion aims to harmonise such standards, potentially opening a market of over 1.4 billion consumers for Indian manufacturers.
Competing claims and uncertainty
While Doraiswami’s optimism is clear, several uncertainties remain. Chinese officials have not quantified future investment commitments, leaving the scale of potential new projects open‑ended. Analysts note that non‑tariff barriers—such as differing safety standards, intellectual‑property enforcement, and bureaucratic red‑tape—have historically slowed Indian firms’ entry into the Chinese market.
Furthermore, geopolitical tensions over the disputed border in the Himalayas continue to flare intermittently, raising the risk that political disputes could spill over into economic negotiations. Some Indian industry groups have expressed caution, warning that deeper Chinese investment could lead to technology transfer that benefits Chinese firms more than Indian ones, or that increased dependence on Chinese capital might constrain India’s strategic autonomy.
What to watch next
– Progress on the comprehensive economic partnership: Detailed negotiations on certification recognition, intellectual‑property rights, and customs simplification will indicate how quickly trade barriers can be lowered.
– Specific Chinese investment projects: Announcements of new joint ventures or greenfield investments in Indian pharma, medical‑device, or engineered‑goods sectors will provide concrete evidence of the ambassador’s call translating into action.
– Trade data trends: Quarterly updates on India‑China export‑import balances will reveal whether Indian exports begin to close the gap with Chinese imports.
– Political developments: Any escalation or de‑escalation of border tensions could either derail or accelerate economic talks, given the close link between security and trade in bilateral relations.
Conclusion
Ambassador Vikram Doraiswami’s briefing underscored a strategic pivot: leveraging record Chinese investment to broaden India’s export footprint, especially in pharmaceuticals, while seeking to address long‑standing trade imbalances through regulatory cooperation. The success of this approach hinges on the ability of both governments to move beyond high‑level statements and resolve concrete barriers—customs procedures, certification standards, and intellectual‑property protections—that have limited Indian market access in China. As Chinese FDI reaches historic highs, the next few months will test whether the diplomatic overture can translate into measurable trade growth and a more balanced economic relationship.
Sources
– “More Chinese investment good for larger relationship, says India’s envoy to China,” The Hindu, 4 July 2026, https://www.thehindu.com/news/international/more-chinese-investment-good-for-larger-relationship-says-indias-envoy-to-china/article71182210.ece
Story synopsis gathered from: The Hindu – National — source
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
